Suppr超能文献

使用镇静催眠药物与痴呆风险:一项系统评价和荟萃分析。

Use of sedative-hypnotic medications and risk of dementia: A systematic review and meta-analysis.

作者信息

AlDawsari Asma, Bushell Trevor J, Abutheraa Nouf, Sakata Shuzo, Al Hussain Sarah, Kurdi Amanj

机构信息

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

Ministry of Health, AlKharj Maternity and Children Hospital, Riyadh, Saudi Arabia.

出版信息

Br J Clin Pharmacol. 2022 Feb;88(4):1567-1589. doi: 10.1111/bcp.15113. Epub 2021 Nov 11.

Abstract

AIMS

Growing evidence suggests an association between the use of sedative-hypnotic medications and risk of dementia. The aim of this study is to examine this association using a meta-analysis approach.

METHODS

MEDLINE (PubMed) and Scopus were systematically searched for studies published in English only. The quality of studies was evaluated using the Newcastle-Ottawa scale, and an overall odds ratio was pooled using a random-effects model.

RESULTS

A total of 35 articles were included in the analysis. Pooled odds ratios (ORs) for dementia from all records were (OR; 1.33, 95% CI 1.19-1.49) for benzodiazepine (BZD) combined use (Subgroup-1), (OR: 1.46, 95% CI 1.23-1.73) for short-acting BZD use (Subgroup-2), (OR: 1.72, 95% CI 1.48-1.99) for long-acting BZD use (Subgroup-3), (OR: 1.13, 95% CI 0.97-1.32) for BZDs without specification of duration of action (Subgroup-4), (OR: 1.64, 95% CI 1.13-2.38) for the combined BZDs and Z-drugs, (OR: 1.43, 95% CI 1.17-1.74) for Z-drugs only, (OR: 1.14, 95% CI 0.88-1.46) for antidepressant use, (OR: 0.97, 95% CI 0.68-1.39) for antipsychotic use and (OR: 0.98, 95% CI 0.85-1.13) for anticonvulsant use. When sensitivity analysis was performed, association between overall use of BZDs and short-acting BZDs with the increased risk of dementia disappeared after exclusion of studies that were not adjusted for age covariate (OR: 1.2, 95% CI 1.0-1.44) and (OR: 1.22, 95% CI 0.75-2.01), respectively. Adjustment for protopathic bias by introduction of a lag period showed no evidence of increased risk of dementia with the use of BZDs (Subgroup-1) (OR: 1.14, 95% CI 0.82-1.58), Z-drugs (OR: 1.29, 95% CI 0.78-2.13), and combined BZDs and Z-drugs (OR: 1.51, 95% CI 0.91-2.53). Combined use of BZDs and Z-drugs showed more positive association when only studies of non-user design were analysed (OR: 2.75, 95% CI 2.23-3.39).

CONCLUSIONS

All the investigated sedative-hypnotics showed no association with increased risk of dementia except for BZDs. However, the observed association with BZDs did not persist after exclusion of studies with potential reverse causation and confounding by indication. Therefore, this association needs to be assessed carefully in future research.

摘要

目的

越来越多的证据表明,使用镇静催眠药物与痴呆风险之间存在关联。本研究的目的是采用荟萃分析方法来检验这种关联。

方法

系统检索MEDLINE(PubMed)和Scopus,仅纳入以英文发表的研究。使用纽卡斯尔-渥太华量表评估研究质量,并采用随机效应模型汇总总体比值比。

结果

分析共纳入35篇文章。所有记录中,苯二氮䓬类药物(BZD)联合使用(亚组1)导致痴呆的合并比值比(OR)为(OR;1.33,95%可信区间1.19 - 1.49),短效BZD使用(亚组2)为(OR:1.46,95%可信区间1.23 - 1.73),长效BZD使用(亚组3)为(OR:1.72,95%可信区间1.48 - 1.99),未明确作用持续时间的BZD(亚组4)为(OR:1.13,95%可信区间0.97 - 1.32),BZD与Z类药物联合使用为(OR:1.64,95%可信区间1.13 - 2.38),仅使用Z类药物为(OR:1.43,95%可信区间1.17 - 1.74),使用抗抑郁药为(OR:1.14,95%可信区间0.88 - 1.46),使用抗精神病药为(OR:0.97,95%可信区间0.68 - 1.39),使用抗惊厥药为(OR:0.98,95%可信区间0.85 - 1.13)。进行敏感性分析时,排除未对年龄协变量进行调整的研究后,BZD总体使用和短效BZD与痴呆风险增加之间的关联消失,调整后的OR分别为(OR:1.2,95%可信区间1.0 - 1.44)和(OR:1.22,95%可信区间0.75 - 2.01)。通过引入滞后时间来调整原发病偏倚后,未发现使用BZD(亚组1)(OR:1.14,95%可信区间0.82 - 1.58)、Z类药物(OR:1.29,95%可信区间0.78 - 2.13)以及BZD与Z类药物联合使用(OR:1.51,95%可信区间0.91 - 2.53)会增加痴呆风险的证据。仅分析非使用者设计的研究时,BZD与Z类药物联合使用显示出更强的正相关(OR:2.75,95%可信区间2.23 - 3.39)。

结论

除BZD外,所有研究的镇静催眠药均未显示与痴呆风险增加有关。然而,在排除具有潜在反向因果关系和指征性混杂的研究后,观察到的BZD与痴呆的关联并未持续存在。因此,这种关联需要在未来的研究中仔细评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验